Header Logo

Connection

VINCENT TAM to Middle Aged

Back to Details
This is a "connection" page, showing publications VINCENT TAM has written about Middle Aged.
VINCENT TAM
Connection Strength
0.793
Middle Aged
  1. Reduction of Vancomycin-Associated Acute Kidney Injury With Montelukast. J Infect Dis. 2025 Jul 30; 232(1):191-198.
    View in: PubMed
    Score: 0.055
  2. Pharmacokinetics of cefiderocol in a patient with carbapenem-resistant Acinetobacter baumannii ventriculitis: A?case report. Pharmacotherapy. 2025 01; 45(1):66-69.
    View in: PubMed
    Score: 0.053
  3. Real life experience with ceftolozane/tazobactam therapy for Pseudomonas aeruginosa bacteremia. J Chemother. 2021 Dec; 33(8):595-597.
    View in: PubMed
    Score: 0.041
  4. Validation of Vancomycin Dosing Guidance During Transition of Care. J Clin Pharmacol. 2021 06; 61(6):806-809.
    View in: PubMed
    Score: 0.040
  5. Population Pharmacokinetics of Polymyxin B. Clin Pharmacol Ther. 2018 09; 104(3):534-538.
    View in: PubMed
    Score: 0.033
  6. Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency. Antimicrob Agents Chemother. 2017 01; 61(1).
    View in: PubMed
    Score: 0.031
  7. Comparative Pharmacokinetic Profiling of Different Polymyxin B Components. Antimicrob Agents Chemother. 2016 11; 60(11):6980-6982.
    View in: PubMed
    Score: 0.030
  8. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study. J Antimicrob Chemother. 2016 12; 71(12):3585-3587.
    View in: PubMed
    Score: 0.030
  9. Impact of hyperglycemia on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2016 Feb; 84(2):155-8.
    View in: PubMed
    Score: 0.028
  10. Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother. 2015; 70(6):1903-7.
    View in: PubMed
    Score: 0.027
  11. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents. 2015 May; 45(5):541-4.
    View in: PubMed
    Score: 0.027
  12. Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin. Antimicrob Agents Chemother. 2014 Nov; 58(11):6946-8.
    View in: PubMed
    Score: 0.026
  13. Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. J Antimicrob Chemother. 2014 Sep; 69(9):2517-21.
    View in: PubMed
    Score: 0.025
  14. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014 May; 58(5):2740-6.
    View in: PubMed
    Score: 0.025
  15. Predictive performance of pharmacokinetic models for outpatients receiving vancomycin continuous infusion. Int J Antimicrob Agents. 2014 Feb; 43(2):197-9.
    View in: PubMed
    Score: 0.025
  16. A model to predict mortality following Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2012 Jan; 72(1):97-102.
    View in: PubMed
    Score: 0.021
  17. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clin Infect Dis. 2011 May; 52(10):1280-1.
    View in: PubMed
    Score: 0.021
  18. Emergence of KPC-producing Klebsiella pneumoniae in Texas. Diagn Microbiol Infect Dis. 2011 Feb; 69(2):234-5.
    View in: PubMed
    Score: 0.020
  19. Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents. 2009 Dec; 34(6):570-4.
    View in: PubMed
    Score: 0.018
  20. Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother. 2008 Dec; 20(6):714-20.
    View in: PubMed
    Score: 0.017
  21. Independent predictors for mortality in patients with positive Stenotrophomonas maltophilia cultures. Ann Acad Med Singap. 2008 Oct; 37(10):826-30.
    View in: PubMed
    Score: 0.017
  22. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008 Mar 15; 46(6):862-7.
    View in: PubMed
    Score: 0.017
  23. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis. 2008 Feb; 60(2):163-7.
    View in: PubMed
    Score: 0.016
  24. Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2007 Jul; 58(3):309-14.
    View in: PubMed
    Score: 0.016
  25. The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia. Diagn Microbiol Infect Dis. 2007 May; 58(1):99-104.
    View in: PubMed
    Score: 0.015
  26. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis. 2005 Sep 01; 41(5):754-7.
    View in: PubMed
    Score: 0.014
  27. Prevalence of the cefazolin inoculum effect (CzIE) in nasal colonizing methicillin-susceptible Staphylococcus aureus in patients from intensive care units in Colombia and use of a modified rapid nitrocefin test for detection. Antimicrob Agents Chemother. 2024 11 06; 68(11):e0089824.
    View in: PubMed
    Score: 0.013
  28. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother. 2003 Jun; 47(6):1853-61.
    View in: PubMed
    Score: 0.012
  29. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother. 2002 Sep; 50(3):425-8.
    View in: PubMed
    Score: 0.011
  30. Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: case report and review. Pharmacotherapy. 2000 Sep; 20(9):1116-9.
    View in: PubMed
    Score: 0.010
  31. Plasma asymmetric dimethylarginine and its association with some of cardiovascular disease risk factors in chronic kidney disease. Med J Malaysia. 2019 06; 74(3):209-214.
    View in: PubMed
    Score: 0.009
  32. Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections. J Chemother. 2017 Feb; 29(1):25-29.
    View in: PubMed
    Score: 0.007
  33. Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients. J Antimicrob Chemother. 2016 Mar; 71(3):727-30.
    View in: PubMed
    Score: 0.007
  34. Enrichment of committed human nucleus pulposus cells expressing chondroitin sulfate proteoglycans under alginate encapsulation. Osteoarthritis Cartilage. 2015 Jul; 23(7):1194-203.
    View in: PubMed
    Score: 0.007
  35. Evaluation of a daptomycin dose-optimization protocol. Am J Health Syst Pharm. 2012 Jun 01; 69(11):979-84.
    View in: PubMed
    Score: 0.006
  36. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin Infect Dis. 2010 Dec 15; 51(12):1406-10.
    View in: PubMed
    Score: 0.005
  37. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother. 2008 Jul; 62(1):168-71.
    View in: PubMed
    Score: 0.004
  38. Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies. Diagn Microbiol Infect Dis. 2006 Mar; 54(3):223-30.
    View in: PubMed
    Score: 0.004
  39. Subcutaneous administration of cefepime. J Pain Symptom Manage. 2005 Aug; 30(2):170-4.
    View in: PubMed
    Score: 0.003
  40. Disposition of cefepime in the central nervous system of patients with external ventricular drains. Pharmacotherapy. 2003 Mar; 23(3):310-4.
    View in: PubMed
    Score: 0.003
  41. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin Infect Dis. 2002 Apr 01; 34(7):922-9.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.